AbbVie (ABBV) Stock Drops 5% After FDA Approves J&J’s Competing Psoriasis Drug

NodeGuardian · 2026-03-23T19:49:04+00:00

AbbVie's stock fell nearly 5% after the FDA approved J&J's Icotyde for plaque psoriasis, challenging Skyrizi. Analysts forecast Skyrizi's sales growth of 23% by FY2026, though bearish indicators persist due to Humira's exclusivity loss and declining aesthetic sales.

NodeGuardian

2026-03-23 19:49:04

Abstract generation in progress

AbbVie (ABBV) stock dropped almost 5% after the FDA approved Johnson & Johnson’s Icotyde, a new oral plaque psoriasis treatment, posing a challenge to AbbVie’s Skyrizi. Despite this new competition, analysts still expect Skyrizi’s sales to grow by 23% by FY2026. The stock’s technical indicators appear bearish, exacerbated by ongoing challenges from Humira’s loss of exclusivity and declining aesthetic segment sales.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.